vTv Therapeutics (FRA:5VT0) NonCurrent Deferred Liabilities: €1.58 Mil (As of Mar. 2026)


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €28.60
GF Value €6,684.42
View Full Analysis

What is vTv Therapeutics NonCurrent Deferred Liabilities?

vTv Therapeutics FRA:5VT0 -3.38% 35 NonCurrent Deferred Liabilities is €1.58 Mil as of Mar. 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,684.42.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

vTv Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was €1.58 Mil.

vTv Therapeutics NonCurrent Deferred Liabilities Related Terms

vTv Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics NonCurrent Deferred Liabilities Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 17.62 17.12 17.83 15.94

vTv Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.27 16.19 15.91 15.94 1.58
FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €1.58 Mil mean?
vTv Therapeutics (FRA:5VT0) has a NonCurrent Deferred Liabilities of €1.58 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on vTv Therapeutics and its competitors.
Is vTv Therapeutics' NonCurrent Deferred Liabilities too high?
vTv Therapeutics' current NonCurrent Deferred Liabilities is €1.58 Mil. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' NonCurrent Deferred Liabilities compare to SMNR and CNTB?
vTv Therapeutics' NonCurrent Deferred Liabilities of €1.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current NonCurrent Deferred Liabilities is €1.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current NonCurrent Deferred Liabilities of €1.58 Mil. The stock's GF Value™ is €6,684.42, compared to a current price of €28.60 — trading 99.6% below its estimated fair value. The current NonCurrent Deferred Liabilities is €1.58 Mil. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current NonCurrent Deferred Liabilities is €1.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €28.60 is trading 99.6% below its estimated GF Value™ of €6,684.42.

Key valuation signals for FRA:5VT0:

  • NonCurrent Deferred Liabilities: €1.58 Mil
  • GF Value™: €6,684.42 vs. price of €28.60 (99.6% below fair value)
  • GF Score™: 35/100

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.60
Price
€6,684.42
GF Value